Compugen Ltd. Announces First-in-Human Clinical Trial of Anti-IL18BP Antibody COM503 in Advanced Solid Tumors at SITC 2025

Reuters

Oct 06

Compugen Ltd. Announces First-in-Human Clinical Trial of Anti-IL18BP Antibody COM503 in Advanced Solid Tumors at SITC 2025

Compugen Ltd. has announced that a trial in progress for its anti-IL18BP antibody, COM503 (GS-0321), will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer $(SITC)$, scheduled for November 7-9, 2025, in National Harbor, Maryland. The first-in-human clinical trial is designed to assess COM503 in participants with advanced solid malignancies. The poster presentation, led by Dr. Manish Sharma, will take place on November 7, 2025. Results from the study have not yet been presented and will be shared at the upcoming conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90856) on October 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573679625"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573679625\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573679625?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573679625","market":"us","top_or_hot":-1,"title":"Compugen Ltd. Announces First-in-Human Clinical Trial of Anti-IL18BP Antibody COM503 in Advanced Solid Tumors at SITC 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compugen Ltd. Announces First-in-Human Clinical Trial of Anti-IL18BP Antibody COM503 in Advanced Solid Tumors at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compugen Ltd. has announced that a trial in progress for its anti-IL18BP antibody, COM503 (GS-0321), will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a>, scheduled for November 7-9, 2025, in National Harbor, Maryland. The first-in-human clinical trial is designed to assess COM503 in participants with advanced solid malignancies. The poster presentation, led by Dr. Manish Sharma, will take place on November 7, 2025. Results from the study have not yet been presented and will be shared at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90856) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compugen Ltd. Announces First-in-Human Clinical Trial of Anti-IL18BP Antibody COM503 in Advanced Solid Tumors at SITC 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompugen Ltd. Announces First-in-Human Clinical Trial of Anti-IL18BP Antibody COM503 in Advanced Solid Tumors at SITC 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compugen Ltd. Announces First-in-Human Clinical Trial of Anti-IL18BP Antibody COM503 in Advanced Solid Tumors at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compugen Ltd. has announced that a trial in progress for its anti-IL18BP antibody, COM503 (GS-0321), will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a>, scheduled for November 7-9, 2025, in National Harbor, Maryland. The first-in-human clinical trial is designed to assess COM503 in participants with advanced solid malignancies. The poster presentation, led by Dr. Manish Sharma, will take place on November 7, 2025. Results from the study have not yet been presented and will be shared at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90856) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL207khQ:1","article_id":"2573679625","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573679625","pubTimestamp":1759748444,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compugen Ltd. has announced that a trial in progress for its anti-IL18BP antibody, COM503 , will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer , scheduled for November 7-9, 2025, in National Harbor, Maryland. The first-in-human clinical trial is designed to assess COM503 in participants with advanced solid malignancies. The poster presentation, led by Dr. Manish Sharma, will take place on November 7, 2025. Results from the study have not yet been presented and will be shared at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire  on October 06, 2025, and is solely responsible for the inf","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK4139":"生物科技","CGEN":"Compugen医疗"},"translate_title":"Compugen Ltd.在SITC 2025上宣布抗IL18BP抗体COM503在晚期实体瘤中的首次人体临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEN":0.9},"content_text":"Compugen Ltd. Announces First-in-Human Clinical Trial of Anti-IL18BP Antibody COM503 in Advanced Solid Tumors at SITC 2025\n    \n\n        Compugen Ltd. has announced that a trial in progress for its anti-IL18BP antibody, COM503 (GS-0321), will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer $(SITC)$, scheduled for November 7-9, 2025, in National Harbor, Maryland. The first-in-human clinical trial is designed to assess COM503 in participants with advanced solid malignancies. The poster presentation, led by Dr. Manish Sharma, will take place on November 7, 2025. Results from the study have not yet been presented and will be shared at the upcoming conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90856) on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}